The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Balloons are as good as stents, but it can be hard to get cardiologists to change their habits.
In a quiet year for medical devices a couple of studies are still worth watching.
Big cap medtech is hiring, largely thanks to organic growth.